1. Home
  2. PPBT vs SNGX Comparison

PPBT vs SNGX Comparison

Compare PPBT & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PPBT
  • SNGX
  • Stock Information
  • Founded
  • PPBT 2010
  • SNGX 1987
  • Country
  • PPBT Israel
  • SNGX United States
  • Employees
  • PPBT N/A
  • SNGX N/A
  • Industry
  • PPBT Biotechnology: Pharmaceutical Preparations
  • SNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PPBT Health Care
  • SNGX Health Care
  • Exchange
  • PPBT Nasdaq
  • SNGX Nasdaq
  • Market Cap
  • PPBT 6.5M
  • SNGX 6.5M
  • IPO Year
  • PPBT N/A
  • SNGX 1987
  • Fundamental
  • Price
  • PPBT $2.27
  • SNGX $1.86
  • Analyst Decision
  • PPBT Strong Buy
  • SNGX
  • Analyst Count
  • PPBT 1
  • SNGX 0
  • Target Price
  • PPBT $33.00
  • SNGX N/A
  • AVG Volume (30 Days)
  • PPBT 286.5K
  • SNGX 26.0K
  • Earning Date
  • PPBT 05-23-2025
  • SNGX 05-09-2025
  • Dividend Yield
  • PPBT N/A
  • SNGX N/A
  • EPS Growth
  • PPBT N/A
  • SNGX N/A
  • EPS
  • PPBT N/A
  • SNGX N/A
  • Revenue
  • PPBT N/A
  • SNGX $2,342.00
  • Revenue This Year
  • PPBT N/A
  • SNGX N/A
  • Revenue Next Year
  • PPBT N/A
  • SNGX N/A
  • P/E Ratio
  • PPBT N/A
  • SNGX N/A
  • Revenue Growth
  • PPBT N/A
  • SNGX N/A
  • 52 Week Low
  • PPBT $2.00
  • SNGX $1.68
  • 52 Week High
  • PPBT $20.60
  • SNGX $14.83
  • Technical
  • Relative Strength Index (RSI)
  • PPBT 40.43
  • SNGX 38.46
  • Support Level
  • PPBT $2.18
  • SNGX $1.83
  • Resistance Level
  • PPBT $2.41
  • SNGX $2.00
  • Average True Range (ATR)
  • PPBT 0.20
  • SNGX 0.10
  • MACD
  • PPBT -0.01
  • SNGX -0.00
  • Stochastic Oscillator
  • PPBT 27.96
  • SNGX 11.11

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: